DANBURY, Conn., Aug. 18 /PRNewswire/ -- TOPEX, Inc. announces the sale of its skin cancer business operations to SENSUS Healthcare, LLC for its low energy SRT 100 superficial radiotherapy treatment system. Since TOPEX received FDA approval during 2007, many systems have been operating worldwide at hospital radiation oncology centers, dermatology and veterinary oncology practices for the treatment of skin cancer. The low energy superficial radiotherapy system provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers, especially primary lesions requiring difficult or extensive surgery with sensitive structures in the head and neck regions -- the fold in the nose, eyelids, lips, corner of the mouth, and the lining of the ear that would otherwise lead to a less than desirable cosmetic outcome. This treatment procedure does not require the use of anesthetics and eliminates the need for skin grafting.
Anthony Pellegrino, TOPEX founder and CEO, stated, "SENSUS Healthcare brings together a highly skilled team of technical sales and marketing professionals for expanding superficial radiotherapy clinical use and business development in the global marketplace."
Joe Sardano, CEO, SENSUS Healthcare stated, "Mr. Pellegrino is recognized for making good technologies better. Physicians and patients alike deserve to have better choices for their treatment. Superficial Radiotherapy provides a non invasive choice to treat skin cancer with appropriate dose levels and proven clinical high cure rates. SENSUS is privileged to offer this technology as well as other products and services to this market segment."
The incidence of skin cancer has steadily increased over the past 75 years. During the 1930s, 1 in 1500 developed skin cancer. In 1960, the rate had risen to 1 in 600 and in 2000, the rate increased to 1 in 66. The National Cancer Institute estimates that 1 out of 5 is now at risk for developing some form of skin cancer during their lifetime. Increased exposure to the sun without skin protection and a decreasing natural ozone layer are cited as the chief causes of this increase. It is estimated that up to 1.3M new skin cancer cases are diagnosed annually in the United States and over 2.5M worldwide. This is projected to increase at a rate of 4% each year.
About TOPEX, Inc. - TOPEX is a technology company focused on the design, manufacture and marketing of products using proprietary strengths in x-ray product design. The company is privately held and based in Danbury, CT.
About SENSUS Healthcare - Taking new aim at skin cancer, SENSUS Healthcare is focused on the design, manufacture and marketing of products and services that incorporate proprietary mobile X-ray technology for cost-effective, non-invasive treatment of non-melanoma skin cancers. The signature SENSUS Healthcare product, the SRT-100, meets stringent safety requirements set by the FDA, UL and ISO/CE Mark certification. Based in Boca Raton, Fla., SENSUS employs best-practice standard operational procedures to ensure quality control, high-grade customer support, optimized success in field operations, and product reliability. For more information, visit www.sensushealthcare.com.
SOURCE TOPEX, Inc.